Who are Cue Biopharma, Inc.'s main suppliers?

Cue Biopharma, Inc. (CUE) key suppliers include: ASCENDANT-HEALTH-SCIENCES-LTD, EINSTEIN, CELG-RI, CELG-RI, Werewolf Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/CUE.

Who are Cue Biopharma, Inc.'s major customers?

Cue Biopharma, Inc. (CUE) key customers include: BOEHRINGER-INGELHEIM, IMSCP, CELG-RI, CELG-RI, Werewolf Therapeutics, Inc. and 3 more. View the full customer network at chainsifter.com/chain/CUE.

What sector is Cue Biopharma, Inc. in?

Cue Biopharma, Inc. (CUE) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Cue Biopharma, Inc. Supplier List (CUE): 5 Verified Suppliers

5Suppliers

8Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Cue Biopharma, Inc. (CUE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

4Distinct source URLs

7High confidence

0.775Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Cue Biopharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ASCENDANT-HEALTH-SCIENCES-LTD	ASCENDANT-HEALTH-SCIENCES-LTD	90%	Securities Purchase Agreement with Ascendant Health Sciences Ltd. In connection with the execution of the License Agreement, on April 30, 2026, the Company and the Licensor also entered into a securi…
EINSTEIN	EINSTEIN	90%	The Einstein License requires the Company to pay a percentage of sublicenses related to the Company’s patent rights for components of its core technology that is licensed from Einstein.
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CUE graph: experienced by many countries in the European Union. The downward pressure on health care costs in general, particu…
CELG-RI	CELG-RI	72%	experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barr…
HOWL	Werewolf Therapeutics, Inc.	72%	Reciprocal relationship from HOWL graph: Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL gra…

Cue Biopharma, Inc. Customers

Ticker	Name	Confidence	Evidence
BOEHRINGER-INGELHEIM	BOEHRINGER-INGELHEIM	92%	On April 1, 2026, Cue Biopharma, Inc. (the “Company”) received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the …
IMSCP	IMSCP	80%	The Company recorded accounts receivable from IMS CP of $ 5.0 million on its condensed consolidated balance sheet as of March 31, 2026 and December 31, 2025.
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CUE graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CUE graph: experienced by many countries i…
CELG-RI	CELG-RI	72%	experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barr…
HOWL	Werewolf Therapeutics, Inc.	72%	Reciprocal relationship from HOWL graph: Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when…
CO-LLC	CO-LLC	62%	of 2025, we incurred license maintenance fees of $1.5 million related to the IMSCP Collaboration and License Agreement, of which $1.0 million was paid in the first quarter of 2026. For the three mont…
LG-CHEM-LTD	LG-CHEM-LTD	62%	expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performan…
ONO-PHARMACEUTICAL-CO-LTD	ONO-PHARMACEUTICAL-CO-LTD	62%	expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performan…

Cue Biopharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CUE-DEBT-8936	Warrants outstanding: 2.7	90%	xbrl warrant detail from xbrl 2017-12-31.
CUE-DEBT	Debt stack $4.0M	90%	Market cache reports total debt of $4.0M.

Cue Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cue Biopharma, Inc..

Cue Biopharma, Inc. Ownership

Holder	Name	Confidence	Evidence
CUE-OWNER-BLEICHROEDER-LP	Bleichroeder LP	90%	13F overlay lists Bleichroeder LP as top holder; 55 tracked holders.

Cue Biopharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ASND	Ascendis Pharma A/S	100.00	2
MRK	Merck & Co., Inc.	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
XLO	Xilio Therapeutics, Inc.	100.00	2
JAZZ	Jazz Pharmaceuticals plc	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	100.00	1	['customer', 'supplier']
PPBT	Purple Biotech Ltd	50.00	2
VYGR	Voyager Therapeutics, Inc.	50.00	2
ZBIO	Zenas BioPharma, Inc.	50.00	2
SMMT	Summit Therapeutics Inc.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
GNLX	Genelux Corporation	50.00	2
TRVI	Trevi Therapeutics, Inc.	50.00	2
INAB	IN8bio, Inc.	50.00	2
RNTX	Rein Therapeutics Inc.	50.00	2
OCUL	Ocular Therapeutix, Inc.	50.00	2
PFE	Pfizer Inc.	50.00	2

Cue Biopharma, Inc. Supply Chain